Definium Therapeutics, Inc. (DFTX)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-11-16. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 30/100 (MEDIUM), 123.2 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 8.89% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Evidence and freshness
Record counts and statuses were computed on 2026-11-21. A source date shows only when we store one; otherwise it says “not recorded”. Spot an error? Report a data error.
| PDUFA / FDA dates | 0 | No records No upcoming FDA decision date found in the company's SEC filings |
SEC 8-K filing |
| Clinical trials | 1 | Current Updated within the last 14 days |
ClinicalTrials.gov source date not recorded · ingested Nov 16, 2026 |
| Insider activity | 0 | Unavailable No record on file; source last refreshed Nov 21, 2026 |
SEC EDGAR Form 4 |
| Dilution risk | 1 | Derived Derived score calculated from SEC data, not a raw record |
DilutionWatch score (derived from SEC filings) source date not recorded · ingested Nov 21, 2026 |
| Short interest | 1 | Current Updated within the last 21 days |
FINRA short interest source date not recorded · ingested Nov 21, 2026 |
| Publications | 2 | Current Updated within the last 30 days |
PubMed source date not recorded · ingested Nov 20, 2026 |
How the signal grade is calculated
The score (0–100) is a weighted average of the source-backed signals we hold for a company: FDA decision date 35%, clinical trials 25%, insider buying 15%, dilution risk 8%, signal convergence 7%, short interest 3%, and 0.5–2% each for smaller signals. A signal we have no record for drops out and the others share its weight. Grades: A ≥ 80, B ≥ 65, C ≥ 50, D ≥ 35, F below 35.
What drives this company's 26.3/100 (grade F):
- Clinical trials: signal score 0.25, weight used 68%, 17.1 points
- Dilution risk: signal score 0.30, weight used 22%, 6.6 points
- Short interest: signal score 0.30, weight used 8%, 2.5 points
- Publications: signal score 0.10, weight used 1%, 0.1 points
Freshness: PDUFA dates that have passed score 0; clinical-trial records older than 90 days are ignored; dilution scores older than 7 days are withdrawn; scores are recalculated daily. Derived signals: the overall score and grade, the dilution-risk score (DilutionWatch, calculated from SEC filings) and signal convergence. The grade is not a forecast of FDA approval, a trial result or a stock move, and not investment advice.
Recent News & SEC Filings
- Definium Therapeutics Eyes 2027 FDA Filing for LSD-Based Drug, Weighs Two Treatment Paths
- Definium Therapeutics: 3 Key Takeaways for Long-Term Investors
- Is Definium Therapeutics (DFTX) Fully Priced After Positive Phase 3 Results?
- How Investors May Respond To Definium Therapeutics Stock After Phase 3 Success
- Definium Therapeutics (DFTX) Following DT120 Phase 3 Data Is The Undervalued Story Intact
- Definium Therapeutics Eyes FDA Filing for LSD Treatment After Three Positive Phase 3 Studies
- Definium (DFTX) Q3 2026 Earnings Call Transcript
- What Definium Therapeutics (DFTX) Said on Its Q3 Earnings Call
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Treatment instability in generalized anxiety disorder (GAD): a U.S. real-world evidence study. — CNS Spectr 2026 Jun 17 PMID 42305036
- The prevalence and burden of generalized anxiety disorder in the United States healthcare system: Real-world prevalence and incidence from 2020 to 2023. — J Mood Anxiety Disord 2026 Mar PMID 41907149
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Definium Therapeutics, Inc..
Full DFTX Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.